BA
BIIB icon

BKS Advisors’s Biogen BIIB Stock Holding History

BKS Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,003
Closed -$354K – 201
2018
Q3 		$354K Sell
1,003
-295
-23% -$102K 0.13% 149
2018
Q2 		$377K Hold
1,298
– – 0.13% 150
2018
Q1 		$355K Buy
1,298
+107
+9% +$33.2K 0.13% 146
2017
Q4 		$379K Sell
1,191
-5
-0.4% -$1.6K 0.14% 140
2017
Q3 		$374K Sell
1,196
-712
-37% -$211K 0.15% 137
2017
Q2 		$518K Buy
1,908
+298
+19% +$78.8K 0.21% 115
2017
Q1 		$440K Buy
+1,610
New +$455K 0.19% 120
2016
Q4 		– Sell
-1,415
Closed -$443K – 191
2016
Q3 		$443K Sell
1,415
-250
-15% -$74K 0.2% 102
2016
Q2 		$403K Buy
1,665
+217
+15% +$57.2K 0.21% 106
2016
Q1 		$377K Buy
+1,448
New +$382K 0.2% 106

Other funds holding BIIB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BKS Advisors's BIIB Position: Q4 2018 in Review

BKS Advisors sold out of Biogen (BIIB) in Q4 2018, closing a stake of 1,003 shares — an estimated $354K sold.

BKS Advisors first reported a position in BIIB in Q1 2016 and held it in 10 quarters. The position peaked at $518K in Q2 2017. 1,140 funds tracked by Wall St. Rank hold BIIB as of Q4 2018.

  • BKS Advisors reported no remaining Biogen position as of Q4 2018 after selling out during the quarter.
  • BKS Advisors sold 1,003 Biogen shares in Q4 2018, an estimated $354K.
  • BKS Advisors first reported a position in Biogen in Q1 2016 and held it in 10 quarters.
  • BKS Advisors's Biogen position peaked at $518K in Q2 2017.
  • 1,140 funds tracked by Wall St. Rank held Biogen as of Q4 2018.

Based on BKS Advisors's 13F filing for Q4 2018, filed 30 Jan 2019.